NOVTU — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• Second Amendment to the Fourth Amended and Restated Credit Agreement

• On May 15, 2026 (the “Second Amendment Effective Date”), we entered into the Second Amendment to the Fourth Amended and Restated Credit Agreement (the “Second Amendment” as amended, the “Credit Agreement”). The Second Amendment, among other things, amends the Credit Agreement to establish $200.0 mil…

• On June 8, 2026, we entered into a securities purchase agreement with institutional and other accredited investors for a private placement of our common shares, which resulted in gross proceeds of approximately $300 million, before placement agent fees and offering expenses of $12.4 million. Under t…

• per share, representing approximately 5.7% of our common shares outstanding immediately following the closing. The placement closed on June 11, 2026, and we recorded net proceeds of approximately $287.6 million as an increase to additional paid-in capital.

• On June 8, 2026, we entered into a definitive agreement to acquire Riverpoint Medical, a category leader in high-growth minimally invasive surgical consumables. On July 23, 2026, we completed the acquisition of all outstanding equity interests of the parent company of Riverpoint Medical for total up…

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• The global economy has continued to face significant challenges, including inflation, supply chain disruptions, business slowdowns, labor shortages, market volatility, and evolving U.S. trade policies such as tariffs and retaliatory measures. Tariffs imposed by the U.S. government on imports from ce…

• Operating income of $27.5 million for the three months ended April 3, 2026 decreased $4.9 million, or 15.1%, from the prior year period. This decrease was attributable to an increase in selling, general and administrative expenses of $8.8 million, and an increase in restructuring, acquisition, and r…

• Basic earnings per common share (“Basic EPS”) of $0.52 for the three months ended April 3, 2026 decreased $0.07 from the prior year period. Diluted earnings per common share (“Diluted EPS”) of $0.51 for the three months ended April 3, 2026 decreased $0.08 from the prior year period. The decreases we…

• Medical Solutions segment revenue for the three months ended April 3, 2026 increased $16.3 million, or 14.8%, versus the prior year period, primarily due to the net impact of $9.0 million revenue contributions from the 2025 acquisition, and an increase in sales of advanced surgery products.

• Medical Solutions segment gross profit for the three months ended April 3, 2026 increased $6.2 million, or 13.5%, versus the prior year period, primarily due to an increase in revenue. Medical Solutions segment gross profit margin was 41.3% for the three months ended April 3, 2026, versus a gross pr…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• Our results of operations will be adversely affected if we fail to identify suitable acquisition candidates, complete acquisitions, successfully integrate recent and future acquisitions or grow the acquired businesses as planned.

• As part of our business strategy, we expect to broaden our product and service offerings by acquiring businesses, technologies, assets and product lines that, we believe, complement or expand our existing businesses. We may have difficulty finding acquisition opportunities, or if we do identify thes…

• Further, our ability to maintain and increase the profitability of acquired businesses will depend on our ability to manage and control operating expenses and to generate and sustain increased levels of revenue. Our expectations to achieve more consistent and predictable levels of revenue and to inc…

• Disruptions in the supply of certain key components and other goods from our suppliers, including limited or single source suppliers, have adversely affected the results of our business operations, and could damage our relationships with customers.

• The production of our products requires a wide variety of raw materials, key components and other goods that are generally available from alternate sources of supply. However, certain critical raw materials, key components and other goods required for the production of some of our principal products…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors during the three months ended July 3, 2026 each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the E…

• (1)This written plan was adopted through a trust for which Mr. Glastra’s spouse is a trustee.

• None of our officers or directors adopted or terminated a “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K, during the three months ended July 3, 2026.

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• No officers or directors adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended April 3, 2026.